Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported a mix of equity awards, vesting and related share sales. On March 1, 2026, she received 14,000 restricted stock units and stock options for 52,000 shares, with RSUs vesting in three equal annual installments and the option vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments.
On March 2, 2026, multiple restricted stock unit tranches were exercised into common stock, and a total of 5,035 common shares were sold at $28.96 per share. Footnotes state these sales were made to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c) and included in prior restricted stock unit agreements. After these transactions, she directly owned 49,328 common shares of Agios common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 5,035 shares ($145,814)
Net Sell
14 txns
Insider
Jones Cecilia
Role
Chief Financial Officer
Sold
5,035 shs ($146K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted stock units | 2,000 | $0.00 | -- |
| Exercise | Restricted stock units | 5,666 | $0.00 | -- |
| Exercise | Restricted stock units | 4,000 | $0.00 | -- |
| Exercise | Restricted stock units | 5,303 | $0.00 | -- |
| Exercise | Common stock | 2,000 | $0.00 | -- |
| Sale | Common stock | 594 | $28.96 | $17K |
| Exercise | Common stock | 5,666 | $0.00 | -- |
| Sale | Common stock | 1,681 | $28.96 | $49K |
| Exercise | Common stock | 4,000 | $0.00 | -- |
| Sale | Common stock | 1,187 | $28.96 | $34K |
| Exercise | Common stock | 5,303 | $0.00 | -- |
| Sale | Common stock | 1,573 | $28.96 | $46K |
| Grant/Award | Restricted stock units | 14,000 | $0.00 | -- |
| Grant/Award | Stock options (right to buy) | 52,000 | $0.00 | -- |
Holdings After Transaction:
Restricted stock units — 0 shares (Direct);
Common stock — 39,394 shares (Direct);
Stock options (right to buy) — 52,000 shares (Direct)
Footnotes (1)
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
FAQ
What insider transactions did AGIO CFO Cecilia Jones report on this Form 4?
Cecilia Jones reported new equity awards, vesting and related share sales. She received restricted stock units and stock options, exercised several restricted stock unit tranches into common stock, and sold shares primarily to cover tax withholding obligations tied to performance share unit vesting.
What new equity awards did the AGIO CFO receive and how do they vest?
She received 14,000 restricted stock units and stock options for 52,000 shares on March 1, 2026. The RSUs vest in three equal annual installments beginning March 1, 2027, while the option vests 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments.
How do the AGIO CFO’s restricted stock units reported here convert into common stock?
Each restricted stock unit represents a contingent right to receive one share of Agios common stock. As RSU grants vest on their stated schedules, vested units convert into common shares, which can then be held or partially sold, including for tax withholding obligations described in the footnotes.